Methods of treating chronic inflammatory diseases
The present invention relates to a peptide, or a salt thereof, comprising or consisting of the amino acid sequence IHMVYSKRSGKPRGYAFIEY, comprising one or more post-translational modifications, for the treatment, prevention or amelioration of a hyper autophagy-related autoimmune disease or disorder.
1. A method of treating or ameliorating a chronic inflammatory or hyper-chaperone-mediated-autophagy(CMA)-related disease or disorder, the method comprising administering to a patient in need thereof a composition comprising an effective amount of at least one peptide selected from the group consisting of SEQ ID NO:1, 2, 4, 5 and a combination thereof, wherein at least one serine in the peptide is phosphorylated, wherein the chronic inflammatory or hyper CMA-related disease or disorder is selected from the group consisting of muscular dystrophy (MD), fibromyalgia, myopathies, chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), asthma, chronic pulmonary obstructive disorder (COPD), eosinophilic airway inflammation, and psoriasis, and the composition is effective in treating or ameliorating at least one symptom of the chronic inflammatory or hyper CMA-related disease or disorder.
2. The method of claim 1 , wherein said chronic inflammatory or hyper-CMA-related disease or disorder is MD.
3. The method of claim 1 , wherein said chronic inflammatory or hyper-CMA-related disease or disorder is fibromyalgia.
4. The method of claim 1 , wherein said chronic inflammatory or hyper-CMA-related disease or disorder is myopathies.
5. The method of claim 1 , wherein said chronic inflammatory or hyper-CMA-related disease or disorder is eosinophilic airway inflammation.
6. The method of claim 1 , wherein said chronic inflammatory or hyper-CMA-related disease or disorder is COPD.
7. The method of claim 1 , wherein said chronic inflammatory or hyper-CMA-related disease or disorder is CIDP.
8. The method of claim 1 , wherein said chronic inflammatory or hyper-CMA-related disease or disorder is asthma.
9. The method of claim 1 , wherein said chronic inflammatory or hyper-CMA-related disease or disorder is psoriasis.
10. The method of claim 1 , wherein the composition is administered at a dosage of from about 100 ng to about 5 mg.
11. The method of claim 10 , wherein the composition further comprises a pharmaceutically acceptable excipient.
12. The method of claim 11 , wherein the excipient is mannitol.
13. The method of claim 1 , wherein the peptide comprises the amino acid sequence of SEQ ID NO:1 including a phosphoserine at position 10.
14. The method of claim 1 , wherein the peptide comprises the amino acid sequence of SEQ ID NO:1 including a phosphoserine at position 10 and an oxidized methionine.
15. The method of claim 1 , wherein the peptide has the structure:
16. The method of claim 1 , wherein the peptide has the structure: